Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine vs Venlafaxine XR in GAD
NCT00122837Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in generalized anxiety disorder (GAD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hamilton Anxiety Rating Scale Total Score Change from Baseline at 10 weeks. Started Apr 2005; status: completed.
02
Drugs
duloxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00122837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122837.